Abstract
Purpose
To develop and optimize a rapid magnetic resonance imaging (MRI) screening protocol for pancreatic cancer to be performed in conjunction with breast MRI screening in breast cancer susceptibility gene (BRCA)–positive individuals.
Methods
An IRB-approved prospective study was conducted. The rapid screening pancreatic MR protocol was designed to be less than 10 min to be performed after a standard breast MRI protocol. Protocol consisted of coronal NT T2 SSFSE, axial NT T2 SSFSE and axial NT rFOV FOCUS DWI, and axial T1. Images were acquired with the patient in the same prone position of breast MRI using the built-in body coil. Image quality was qualitatively assessed by two radiologists with 12 and 13 years of MRI experience, respectively. The imaging protocol was modified until an endpoint of five consecutive patients with high-quality diagnostic images were achieved. Signal-to-noise ratio and contrast-to-noise ratio were assessed.
Results
The rapid pancreas MR protocol was successfully completed in all patients. Diagnostic image quality was achieved for all patients. Excellent image quality was achieved for low b values; however, image quality at higher b values was more variable. In one patient, a pancreatic neuroendocrine tumor was found and the patient was treated surgically. In four patients, small pancreatic cystic lesions were detected. In one subject, a hepatic mass was identified and confirmed as adenoma by liver MRI.
Conclusion
Rapid MR protocol for pancreatic cancer screening is feasible and has the potential to play a role in screening BRCA patients undergoing breast MRI.
Key Point
• Develop and optimize a rapid magnetic resonance imaging (MRI) screening protocol for pancreatic cancer to be performed in conjunction with breast MRI screening in BRCA mutation positive individuals.
Similar content being viewed by others
Abbreviations
- ADC:
-
Apparent diffusion coefficient
- ANOVA:
-
Analysis of variance
- BRCA:
-
Breast-related cancer antigens
- CI:
-
Confidence interval
- CNR:
-
Contrast-to-noise ratio
- EUS:
-
Endoscopic ultrasound
- FNA:
-
Fine needle biopsy
- FOCUS DWI:
-
Field-of-view optimized and constrained undistorted single-shot diffusion-weighted imaging
- FSPGR:
-
Fast spoiled gradient echo
- ICC:
-
Intra-class correlation coefficient
- IPMN:
-
Intraductal papillary mucinous neoplasms
- MRCP:
-
Magnetic resonance cholangiopancreatography
- MRI:
-
Magnetic resonance imaging
- NEX:
-
Number of excitations
- NT:
-
Navigator-triggered
- PDAC:
-
Pancreatic ductal adenocarcinoma
- pNET:
-
Pancreatic neuroendocrine tumor
- RC:
-
Repeatability coefficient
- ROI:
-
Regions-of-interest
- SNR:
-
Signal-to-noise ratio
- SSFSE:
-
Single-shot fast spin echo
References
Greer JB, Whitcomb DC (2007) Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 56:601–605
Chang MC, Wong JM, Chang YT (2014) Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol 20:2358–2364
Holter S, Borgida A, Dodd A et al (2015) Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124–3129
Golan T, Oh D-Y, Reni M et al (2016) POLO: a randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (g BRCA m). J Clin Oncol 4:15 TPS4152–TPS4152
Canto MI, Harinck F, Hruban RH et al (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62:339–347
Vasen H, Ibrahim I, Ponce CG et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 34:2010–2019
Gradishar WJ, Anderson BO, Blair SL et al (2014) National comprehensive cancer network breast cancer panel. J Natl Compr Canc Netw 3:542–590
Lee MV, Katabathina VS, Bowerson ML et al (2017) BRCA-associated cancers: role of imaging in screening, diagnosis, and management. Radiographics 37:1005–1023
Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7:60
Golan T, Kanji ZS, Epelbaum R et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132–1138
Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785
Al-Sukhni W, Borgida A, Rothenmund H et al (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16:771–783
Canto MI, Hruban RH, Fishman EK et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142:796–804 quiz e714–795
Langer P, Kann PH, Fendrich V et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58:1410–1418
Ludwig E, Olson SH, Bayuga S et al (2011) Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 106:946–954
Vasen HF, Wasser M, van Mil A et al (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140:850–856
Verna EC, Hwang C, Stevens PD et al (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028–5037
Manfredi R, Pozzi Mucelli R (2016) Secretin-enhanced MR imaging of the pancreas. Radiology 279:29–43
Giovannetti G, Hartwig V, Positano V, Vanello N (2014) Radiofrequency coils for magnetic resonance applications: theory, design, and evaluation. Crit Rev Biomed Eng 42:109–135
Lutterbey G, Behrends K, Falkenhausen M et al (2007) Is the body-coil at 3 tesla feasible for the MRI evaluation of the painful knee? A comparative study. Eur Radiol 17:503–508
Willinek WA, Schild HH (2008) Clinical advantages of 3.0 T MRI over 1.5 T. Eur J Radiol 65:2–14
Lavdas I, Miquel ME, McRobbie DW, Aboagye EO (2014) Comparison between diffusion-weighted MRI (DW-MRI) at 1.5 and 3 tesla: a phantom study. J Magn Reson Imaging 40:682–690
Vasanawala SS, Iwadate Y, Church DG, Herfkens RJ, Brau AC (2010) Navigated abdominal T1-W MRI permits free-breathing image acquisition with less motion artifact. Pediatr Radiol 40:340–344
Bamrungchart S, Tantaway EM, Midia EC et al (2013) Free breathing three-dimensional gradient echo-sequence with radial data sampling (radial 3D-GRE) examination of the pancreas: comparison with standard 3D-GRE volumetric interpolated breathhold examination (VIBE). J Magn Reson Imaging 38:1572–1577
Korn N, Kurhanewicz J, Banerjee S, Starobinets O, Saritas E, Noworolski S (2015) Reduced-FOV excitation decreases susceptibility artifact in diffusion-weighted MRI with endorectal coil for prostate cancer detection. Magn Reson Imaging 33:56–62
Ma C, Li YJ, Pan CS et al (2014) High resolution diffusion weighted magnetic resonance imaging of the pancreas using reduced field of view single-shot echo-planar imaging at 3 T. Magn Reson Imaging 32:125–131
Fukukura Y, Shindo T, Hakamada H et al (2016) Diffusion-weighted MR imaging of the pancreas: optimizing b-value for visualization of pancreatic adenocarcinoma. Eur Radiol 26:3419–3427
Barral M, Taouli B, Guiu B et al (2015) Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology 274:45–63
Herrmann J, Schoennagel BP, Roesch M et al (2013) Diffusion-weighted imaging of the healthy pancreas: ADC values are age and gender dependent. J Magn Reson Imaging 37:886–891
Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781 quiz 665
Shoushtari AN, Covey AM, Zaatari G et al (2014) A woman with metastatic pancreatic neuroendocrine tumor. Gastrointest Cancer Res 7:27–32
Acknowledgements
The authors would like to thank Laura Tang, Department of Pathology, Memorial Sloan Kettering Cancer Center, for her assistance in the histopathological analysis.
Funding
- This work was supported by the National Institutes of Health (Grant P30 CA008748).
- Supported in part by a grant from the Lustgarten Foundation for Pancreas Cancer Research (DK).
- Work from Giuseppe Corrias was partially supported by a scholarship awarded by ISSNAF Imaging Science Chapter.
The funding sources had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Lorenzo Mannelli.
Conflict of interest
The authors of this manuscript declare relationships with the following companies:
Maggie Fung, PhD works for GE Healthcare, Global MR Applications and Workflow, New York, NY, United States.
Statistics and biometry
Marinela Capanu, PhD, and Junting Zheng, MS, kindly provided statistical advice for this manuscript.
Marinela Capanu, PhD, and Junting Zheng, MS, are of the authors and have significant statistical expertise.
Informed consent
Only if the study is on human subjects:
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional Review Board approval was obtained.
Methodology
• prospective
• observational
• performed at one institution
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 1768 kb)
Rights and permissions
About this article
Cite this article
Corrias, G., Raeside, M.C., Agostini, A. et al. Pilot study of rapid MR pancreas screening for patients with BRCA mutation. Eur Radiol 29, 3976–3985 (2019). https://doi.org/10.1007/s00330-018-5975-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-018-5975-0